Patent ID: 6429009
Filing Date: 2002-08-06
Classification: A61K,A61P,C07K,C12N

Abstract:
A composition comprising a recombinant retroviral expression vector comprising a replication-defective, nonproducing, interfering, modified human immunodeficiency virus type 1 (HIV-1) F12 proviral genome, wherein said F12 proviral genome has been modified by deletion of the 3â€²LTR and a portion of the nef coding region, and said genome is inserted into the expression vector in an antisense orientation with respect to the transcription direction of the vector, wherein said recombinant vector is capable of stably transfecting or transducing the modified provirus into CD4+ human cells and expressing the F12 proviral genome in quantities sufficient to confer resistance to HIV-1 or HIV-2 superinfection of said CD4+ human cells.